Advancing Drug Innovation for Neglected Diseases—Criteria for Lead Progression

The current drug R&D pipeline for most neglected diseases remains weak, and unlikely to support registration of novel drug classes that meet desired target product profiles in the short term. This calls for sustained investment as well as greater emphasis in the risky upstream drug discovery. Ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Nwaka, Solomon, Ramirez, Bernadette, Brun, Reto, Maes, Louis, Douglas, Frank, Ridley, Robert
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727960/
https://www.ncbi.nlm.nih.gov/pubmed/19707561
http://dx.doi.org/10.1371/journal.pntd.0000440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727960/
https://www.ncbi.nlm.nih.gov/pubmed/19707561
http://dx.doi.org/10.1371/journal.pntd.0000440

Ejemplares similares